Menu
Back to Journals » Journal of Experimental Pharmacology » Volume 4
Investigational agents in metastatic basal cell carcinoma: focus on vismodegib
Authors Batty N, Kossoff E, Dy G
Received 5 April 2012
Accepted for publication 30 May 2012
Published 31 August 2012 Volume 2012:4 Pages 97—103
DOI https://doi.org/10.2147/JEP.S26591
Review by Single anonymous peer review
Peer reviewer comments 6
Nicolas Batty,1 Ellen Kossoff,2 Grace K Dy1
1Department of Medicine, Roswell Park Cancer Center, Buffalo, NY, USA; 2Department of Pharmacy, Roswell Park Cancer Center, Buffalo, NY, USA
Abstract: Vismodegib (GDC-0449, 2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide, Erivedge™) is a novel first-in-human, first-in class, orally bioavailable Hedgehog pathway signaling inhibitor of the G-protein coupled receptor-like protein smoothened (SMO) which was approved in the United States on January 2012. This signaling pathway is involved in the carcinogenesis of several types of tumor, as exemplified by basal cell carcinoma. This review focuses on the role of the Hedgehog pathway in the pathogenesis of basal cell carcinoma, the pharmacology and the clinical activity of vismodegib, as well as a brief summary of investigational agents in development targeting this pathway.
Keywords: hedgehog inhibitors, metastatic basal cell carcinoma, hedgehog signalling pathway
© 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.